MoonLake Q3: $498.5M Cash, BLA Acceptance Decision Due by End-November
MLTX sits 23% above its 52-week low of $9.46.
Summary
MoonLake reported Q3 2026 results with $498.5 million in cash and a runway to mid-2028, and said the FDA will decide by end-November whether to accept its sonelokimab BLA for review, with a PDUFA date and Priority Review decision by mid-December.
Key Events · Earnings and Guidance · MLTX
-
Q3 Cash Position and Runway
Ended September 30, 2026 with $498.5 million in cash, cash equivalents and short-term marketable debt securities, down from $537 million at June 30; management expects funding to mid-2028.
-
R&D Jump on BLA Milestone Accrual
R&D expense rose to $68.9 million from $50.2 million, an $18.7 million increase primarily from accrued milestone license fees tied to the expected BLA acceptance. Net loss was $79.5 million, or $0.93 per share.
-
FDA Acceptance Decision Due Late November
BLA for sonelokimab in moderate-to-severe HS was submitted September 30, 2026; a decision on acceptance for review is expected by end-November 2026, with PDUFA date allocation and a Priority Review decision by mid-December 2026.
-
Non-Dilutive Debt Capacity Remains
Up to $400 million remains available under the Hercules Capital debt facility, alongside the ATM program upsized to $300 million in August 2026.
Analysis · MLTX · Life Sciences
The quarter's headline is the balance sheet and the regulatory clock. MoonLake burned $79.5 million in Q3 and ended September with $498.5 million in cash and short-term securities, which management says funds operations into mid-2028 — past the expected H2 2027 US launch of sonelokimab in hidradenitis suppurativa if approved. R&D jumped to $68.9 million from $50.2 million, driven by an $18.7 million accrual for a milestone license fee tied to the expected BLA acceptance, so part of the higher spend is a one-time regulatory trigger rather than a permanent step-up. The near-term swing factor is the FDA: a decision on whether the BLA is accepted for review is expected by end-November 2026, with a PDUFA date and a Priority Review decision by mid-December. A refusal-to-file or a standard (rather than priority) review would reset the launch timeline; acceptance keeps the H2 2027 launch plan intact. The up-to-$400 million Hercules facility remains undrawn headroom and is non-dilutive, which matters because the ATM was upsized to $300 million in August.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $11.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $9.46 to $23.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.